These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1420016)

  • 21. The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results.
    Burger HG; Hailes J; Menelaus M; Nelson J; Hudson B; Balazs N
    Maturitas; 1984 Dec; 6(4):351-8. PubMed ID: 6442755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality.
    Davis SR; McCloud P; Strauss BJ; Burger H
    Maturitas; 1995 Apr; 21(3):227-36. PubMed ID: 7616872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants.
    Savvas M; Bishop J; Laurent G; Watson N; Studd J
    Br J Obstet Gynaecol; 1993 Feb; 100(2):154-6. PubMed ID: 8476808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women.
    Mc Manus J; Mc Eneny J; Thompson W; Young IS
    Atherosclerosis; 1997 Nov; 135(1):73-81. PubMed ID: 9395275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term hormone implant therapy--effects on lipoproteins and steroid levels in post-menopausal women.
    Fletcher CD; Farish E; Hart DM; Barlow DH; Gray CE; Conaghan CJ
    Acta Endocrinol (Copenh); 1986 Mar; 111(3):419-23. PubMed ID: 3962567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An audit of oestradiol levels and implant frequency in women undergoing subcutaneous implant therapy.
    Buckler HM; Kalsi PK; Cantrill JA; Anderson DC
    Clin Endocrinol (Oxf); 1995 May; 42(5):445-50. PubMed ID: 7621560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endometrial and menstrual response to subcutaneous oestradiol and testosterone implants and continuous oral progestogen therapy in post-menopausal women.
    Magos AL; Brincat M; O'Dowd T; Wardle PJ; Schlesinger P; Studd JW
    Maturitas; 1985 Nov; 7(4):297-302. PubMed ID: 4079826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endometrial response to a cyclic regimen of percutaneous 17beta-estradiol and low-dose vaginal micronized progesterone in women with mild-to-moderate hypertension.
    Vilodre LC; Osório Wender MC; Sisson de Castro JA; dos Reis FM; Ruschel S; Magalhães JA; Spritzer PM
    Gynecol Endocrinol; 2003 Aug; 17(4):323-8. PubMed ID: 14503977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern.
    Christiansen C; Riis BJ
    Br J Obstet Gynaecol; 1990 Dec; 97(12):1087-92. PubMed ID: 2126198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy.
    Hirvonen E; Lamberg-Allardt C; Lankinen KS; Geurts P; Wilén-Rosenqvist G
    Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():19-25. PubMed ID: 9389779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex hormone-binding globulin and antithrombin III activity in women with oral ultra-low-dose estradiol.
    Matsui S; Yasui T; Kasai K; Keyama K; Yoshida K; Kato T; Uemura H; Kuwahara A; Matsuzaki T; Irahara M
    J Obstet Gynaecol; 2017 Jul; 37(5):627-632. PubMed ID: 28317410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endometrial and vaginal response to three different oestrogen preparations administered by the transdermal and oral routes.
    Johannisson E; Landgren BM; Diczfalusy E
    Maturitas; 1988 Oct; 10(3):181-92. PubMed ID: 3185292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endogenous sex hormones and bone mineral density among community-based postmenopausal women.
    Murphy S; Khaw KT; Sneyd MJ; Compston JE
    Postgrad Med J; 1992 Nov; 68(805):908-13. PubMed ID: 1494513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postmenopausal bone loss: does HRT always work?
    Stevenson JC; Hillard TC; Lees B; Whitcroft SI; Ellerington MC; Whitehead MI
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 2():88-91. PubMed ID: 8252111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oestradiol and testosterone implants.
    Studd JW; Smith RN
    Baillieres Clin Endocrinol Metab; 1993 Jan; 7(1):203-23. PubMed ID: 8435053
    [No Abstract]   [Full Text] [Related]  

  • 36. [Variability of bone response to hormone replacement therapy].
    Ruiz JC; Tamborini A; Neftel P; Bosio-Le Goux B; Lecuru F; Taurelle R
    Rev Fr Gynecol Obstet; 1995; 90(5-6):263-4, 267-74. PubMed ID: 7569587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of transdermal estrogen therapy on bone mass and turnover in early postmenopausal smokers: a prospective, controlled study.
    Välimäki MJ; Laitinen KA; Tähtelä RK; Hirvonen EJ; Risteli JP
    Am J Obstet Gynecol; 2003 Nov; 189(5):1213-20. PubMed ID: 14634543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of menopausal oestrogen deficiency symptoms in hysterectomised women by means of 17beta-oestradiol pellet implants.
    Staland B
    Acta Obstet Gynecol Scand; 1978; 57(3):281-5. PubMed ID: 665176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause.
    Chakravarti S; Collins WP; Thom MH; Studd JW
    Br Med J; 1979 Apr; 1(6169):983-5. PubMed ID: 219937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oestrogens, gonadotrophins and SHBG during oral and cutaneous administration of oestradiol-17 beta to menopausal women.
    Fåhraeus L; Larsson-Cohn U
    Acta Endocrinol (Copenh); 1982 Dec; 101(4):592-6. PubMed ID: 6818806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.